China's Huahai spots bulk manufacturing opportunities amid upcoming patent expiries
This article was originally published in Scrip
Executive Summary
With a number of big-selling drugs facing patent expiration, Chinese pharma companies are gearing up for the mass production of generic versions, Huahai Pharmaceutical being one recent example.